WEBULL
WebtradeDownload

The Bull Case For DENTSPLY SIRONA (XRAY) Could Change Following Profitability Return And Conference Spotlight - Learn Why

Simply Wall St · 1d ago
  • DENTSPLY SIRONA recently reported second quarter 2026 results that brought the company back to profitability despite a year-on-year decline in net sales, and it is scheduled to present at the Baird 2026 Global Healthcare Conference.
  • This return to profitability, combined with ongoing industry headwinds and a valuation that some investors view as potentially undervalued, has sharpened focus on how effectively the company can execute its recovery plans.
  • We’ll now examine how DENTSPLY SIRONA’s return to profitability could influence its investment narrative and the outlook for its dental platform.

This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.

DENTSPLY SIRONA Investment Narrative Recap

To own DENTSPLY SIRONA, you need to believe its dental platform can translate a complex turnaround into steadier growth and healthier margins over time. The key near term catalyst is whether the recent return to profitability can be sustained while sales remain pressured, especially in weaker U.S. categories. The biggest risk is that persistent top line softness and tariff related cost pressures keep eroding margins. The latest results help sentiment but do not remove that execution risk.

Among recent announcements, the expanded Medline Sinclair distribution agreement in Canada looks most relevant. It directly supports the company’s push into higher value digital dentistry, which many investors see as central to its recovery story. If these partnerships help drive adoption of DS Core and connected equipment, they could reinforce the earnings impact of the move back to profitability, though the benefits may take time to show up in reported sales and margins.

Yet beneath the return to profit, investors should be aware of the ongoing risk from tariff driven cost pressures and soft demand in higher margin categories...

Read the full narrative on DENTSPLY SIRONA (it's free!)

DENTSPLY SIRONA's narrative projects $3.8 billion revenue and $189.7 million earnings by 2029.

Uncover how DENTSPLY SIRONA's forecasts yield a $13.40 fair value, a 18% upside to its current price.

Exploring Other Perspectives

XRAY 1-Year Stock Price Chart
XRAY 1-Year Stock Price Chart

While consensus focuses on gradual repair, the most optimistic analysts saw US$3.9 billion of revenue and US$373 million of earnings by 2029, highlighting how views on digital platform upside and cost discipline can differ sharply and may shift again after this latest profitability milestone.

Explore 3 other fair value estimates on DENTSPLY SIRONA - why the stock might be worth just $13.40!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

  • A great starting point for your DENTSPLY SIRONA research is our analysis highlighting 4 key rewards that could impact your investment decision.
  • Our free DENTSPLY SIRONA research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DENTSPLY SIRONA's overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.